Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Ironwood Pharmaceuticals Announces Approval of LINZESS linaclotide in China for the Treatment of Adults with IBSC

Wednesday, January 16, 2019

Zambon SpA an international pharmaceutical company strongly committed to the central nervous system CNS therapeutic area and Valeo Pharma Inc a specialty pharmaceutical company dedicated to commercializing innovative prescription products in Canada today announce the approval of Onstryv safinamide f..

Menlo Therapeutics Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis

Wednesday, January 16, 2019

Menlo Therapeutics Inc a latestage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus itch today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation for serlopitant for the treatment of pruritus associated..

Clinigen Extends Exclusive European Clinical Trial Sourcing and Supply Agreement with Accord Healthcare

Friday, January 11, 2019

Clinigen Group plc the global pharmaceutical and services company announces that its Clinical Trial Service CTS business has extended its exclusive European clinical trial supply agreement with Accord Healthcare Accord Clinigen is also offering pharma companies an on demand service to Accords produc..

Chinese API Market Growing Strongly CPhI China Assisting Enterprises with the Transformation Innovation and Comprehensive Upgrading

Friday, January 11, 2019

As China continues to advance from a big country in pharmaceuticals to a power in pharmaceuticals and the global economy maintains good trends the main business income of API manufacturing in China has reached RMB 4991 billion growing by 1468 year on year and the export of APIs has reached USD 291 b..

EVENITY romosozumab Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

Friday, January 11, 2019

Amgen and UCB today announced that the Japanese Ministry of Health Labor and Welfare has granted a marketing authorization for EVENITY romosozumab for the treatment of osteoporosis in patients at high risk of fracture Amgen and UCB are codeveloping EVENITY worldwide with development in Japan being l..

Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG300 for the Treatment of Patients with Beta Thalassemia

Thursday, January 10, 2019

Protagonist Therapeutics Inc today announced that the first patient has been dosed in the Phase 2 study of PTG300 an injectable hepcidin mimetic peptide in development for the treatment of patients with beta thalassemia a rare disease characterized by chronic anemia and iron overload The study is de..

Aphria Completes Acquisition of CC Pharma Leading German Pharmaceutical and Medical Cannabis Distributor

Thursday, January 10, 2019

Aphria Inc today announced that it had completed its previously announced acquisition of CC Pharma GmbH CC Pharma a leading distributor of pharmaceutical products including medical cannabis to more than 13000 pharmacies in Germany as well as throughout Europe The Company continues to strengthen its ..

PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and CostEffectively

Wednesday, January 09, 2019

PAREXEL International Corporation a leading innovator of global biopharmaceutical services today introduced a new dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and costeffectively PAREXEL Biotech builds on the Companys..

Sandoz and Pear Therapeutics Announce US Launch of reSETOTM to Help Treat Opioid Use Disorder

Wednesday, January 09, 2019

Sandoz Inc a Novartis division and Pear Therapeutics Inc announced today the US commercial launch of reSETOTM for patients with Opioid Use Disorder OUD reSETO cleared by the US Food and Drug Administration FDA in December is immediately available The reSETO prescription digital therapeutic PDT is..

Sublimity Therapeutics Receives Investigational New Drug IND Clearance from US Food and Drug Administration FDA

Tuesday, January 08, 2019

Sublimity Therapeutics a specialty pharmaceutical company focused on the treatment of ulcerative colitis announced today that the company has received FDA clearance to proceed with its phase 2b clinical trial of the companys lead drug candidate ST0529 The aim of this multicenter randomized doublebli..

Decibel Therapeutics and Cocoon Biotech Announce Collaboration to Develop Proprietary Formulations for Delivery of Medicines to the Inner Ear

Tuesday, January 08, 2019

Decibel Therapeutics and Cocoon Biotech today announced a research collaboration to apply Cocoon39s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders As part of this agreement Cocoon and Decibel will jointly conduct research into drug formulations..

Takeda Announces the Legal Approval of the Settlement Agreement for the Acquisition of Shire plc

Monday, January 07, 2019

Takeda Pharmaceutical Company Limited announces the announcement of Shire plc Shire today that approval by the Royal Court of Jersey the Jersey Court in respect of the Settlement Agreement the Scheme of Arrangement or Scheme pursuant to which the proposed acquisition of Shire by Takeda the Takeover ..

Oculis Expands Portfolio with the InLicensing of a Novel Phase IIstage AntiTNF Alpha Antibody Fragment

Monday, January 07, 2019

Oculis SA a clinicalstage biopharmaceutical company developing nextgeneration topical ophthalmic treatments has entered into an agreement to in license a novel topical antiTNF alpha antibody from Novartis No financial details are disclosed The compound named LME 636 is based on a proprietary sing..

Velabs Therapeutics to Cooperate with BioMed X in the Field of Immunology

Monday, January 07, 2019

Velabs Therapeutics specializing in the fast generation of functional therapeutic antibodies today announced that it has entered into a collaboration agreement with BioMed X Innovation Center Heidelberg The collaboration will capitalize on Velabs microfluidicsbased technology in the field of Tcell s..

Takeda announces multiple collaborations in cell therapies to advance the companys new portfolio of immunooncology

Saturday, January 05, 2019

Takeda Pharmaceutical Company Limited today announced new collaborations in immunocompromised research IO for the company Through these collaborations Takeda seeks to accelerate the discovery of nextgeneration cancer immunotherapies including new approaches to cell therapies which may offer importan..

Ablexis Announces Licensing Agreement with Corvidia Therapeutics

Saturday, January 05, 2019

Ablexis LLC a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery today announced a license agreement with Corvidia Therapeutics Inc The nonexclusive license grants Corvidia rights to use the AlivaMab Mouse for antibody drug discovery and developm..

Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies

Friday, January 04, 2019

Science 37 an industry leader in virtual clinical trials and Boehringer Ingelheim announced today a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials Science 37 is licensing access to its proprietary software platform NORA Network ..

Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform

Friday, January 04, 2019

Amunix Pharmaceuticals Inc Amunix a biopharmaceutical company focused on the discovery and development of novel immunooncology therapeutics today announced that it has entered into a licensing agreement with Merck known as MSD outside the United States and Canada for rights to develop therapeutics a..

Rentschler Biopharma Completes Acquisition of US Manufacturing Site

Friday, January 04, 2019

Rentschler Biopharma SE a leading contract development and manufacturing organization CDMO for biopharmaceuticals announced today that the Company has completed the acquisition of a manufacturing facility from an affiliate of Shire plc The 93000 square foot site is located near Boston in Milford MA ..

SOL Global Announces Investment in and Strategic Partnership with European Medical Cannabis and CBD Firm GreenLight Pharmaceuticals Ltd

Thursday, January 03, 2019

SOL Global Investments Corp is pleased to announce an investment in and strategic partnership with European medical cannabis company GreenLight Pharmaceuticals Ltd GreenLight Pharmaceuticals or GreenLight GreenLight which was founded in 2014 and is headquartered in Dublin Ireland is a verticallyi..